- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04059913
Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
A Prospective, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease
This is a randomized, open-label, multi-center study in dialysis chronic kidney disease (CKD) participants to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period.
There are 3 study periods:
- Screening Period (up to 4 weeks)
- Treatment Period (36 weeks)
Part 1: Correction/Conversion Period (Weeks 1-20)
Part 2: Hemoglobin (Hb) Maintenance Period (Weeks 21-36)
- Follow-up Period (4 weeks)
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Approximately 102 erythropoiesis stimulating agents (ESA)-naïve participants and 204 ESA-treated participants will be enrolled and randomized respectively in a 1:1 ratio to receive roxadustat at one of 2 starting doses as below:
- Low weight-based dosing: 70 milligrams (mg) 3 times a week (TIW) for body weight <60 kilograms (kg) or 100 mg TIW for body weight ≥60 kg
- Standard weight-based dosing: 100 mg TIW for body weight <60 kg or 120 mg TIW for body weight ≥60 kg
After 20 weeks of treatment, all eligible participants whose last 2 Hb levels ≥105 grams (g)/liter (L) and change in Hb over the most recent 4 weeks is > - 10 g/L will switch to receive roxadustat for another 16 weeks to evaluate the efficacy and safety of new dosing regimens.
At the end of Week 36, all participants will discontinue roxadustat and enter a 4-week Follow-up Period.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Beijing, Kina, 100044
- Investigational Site
-
Beijing, Kina, 100191
- Investigational Site
-
Beijing, Kina, 100730
- Investigational Site
-
Shanghai, Kina, 200025
- Investigational Site
-
Tianjin, Kina, 300052
- Investigational Site
-
-
Anhui
-
Hefei, Anhui, Kina, 230601
- Investigational Site
-
-
Gansu
-
Lanzhou, Gansu, Kina, 730030
- Investigational Site
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510515
- Investigational Site
-
Shenzhen, Guangdong, Kina, 518020
- Investigational Site
-
-
Guangxi Province
-
Nanning, Guangxi Province, Kina, 530021
- Investigational Site
-
-
Henan
-
Zhengzhou, Henan, Kina, 450052
- Investigational Site
-
-
Hubei
-
Wuhan, Hubei, Kina, 430060
- Investigational Site
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Investigational Site
-
-
Inner Mongolia Autonomous Region
-
Baotou, Inner Mongolia Autonomous Region, Kina, 014010
- Investigational Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210009
- Investigational Site
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Investigational Site
-
-
Jilin
-
Chang chun, Jilin, Kina, 130021
- Investigational Site
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110004
- Investigational Site
-
Shenyang, Liaoning, Kina, 110122
- Investigational Site
-
-
Shanxi
-
Taiyuan, Shanxi, Kina, 030001
- Investigational Site
-
Xi'an, Shanxi, Kina, 710004
- Investigational Site
-
Xi'an, Shanxi, Kina, 710061
- Investigational Site
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Investigational Site
-
Chengdu, Sichuan, Kina, 610072
- Investigational Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
1. CKD with end-stage renal disease (ESRD) on either hemodialysis (HD) or peritoneal dialysis (PD)
Exclusion Criteria:
- Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab).
- Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event (for example, deep venous thrombosis or pulmonary embolism) within 26 weeks prior to Day 1.
- History of malignancy, myelodysplastic syndrome, and multiple myeloma.
- Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (for example, systemic lupus erythematosis [SLE], rheumatoid arthritis, celiac disease).
- Clinically significant gastrointestinal bleeding.
- Women of childbearing potential and men with sexual partners of child bearing potential who are not using adequate contraception.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Part 1: ESA-Naïve Participants - Low Weight Based Dosing
ESA-naïve participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Andre navn:
|
Eksperimentell: Part 1: ESA-Naïve Participants - Standard Weight Based Dosing
ESA naïve participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Andre navn:
|
Eksperimentell: Part 1: ESA-Treated Participants - Low Weight Based Dosing
ESA-treated participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Andre navn:
|
Eksperimentell: Part 1: ESA-Treated Participants - Standard Weight Based Dosing
ESA treated participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Andre navn:
|
Eksperimentell: Part 2: Roxadustat QW
Participants will receive roxadustat once a week (QW).
Roxadustat dose will be 2-dose step increase from originally planned week 21 TIW per dose amount.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Andre navn:
|
Eksperimentell: Part 2: Roxadustat BIW
Participants will receive roxadustat twice a week (BIW).
Roxadustat dose will be 1-dose step increase from originally planned week 21 TIW per dose amount.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Andre navn:
|
Eksperimentell: Part 2: Roxadustat TIW
Participants will receive roxadustat TIW.
Roxadustat dose will continue per dose adjustment guideline.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Part 1 (ESA Naïve): Percentage of Participants who Achieved Hb ≥110 g/L in the First 20 Weeks
Tidsramme: Weeks 1 to 20
|
Weeks 1 to 20
|
Part 1 (ESA Treated): Percentage of Participants who Achieved Mean Hb ≥100 g/L Averaged Over Weeks 17 to 21 Visits
Tidsramme: Weeks 17 to 21
|
Weeks 17 to 21
|
Part 2: Mean Hb Value Averaged Over Weeks 33 to 37 Visits
Tidsramme: Weeks 33 to 37
|
Weeks 33 to 37
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Part 1: Mean Change in Hb Level From Baseline to Average Over Weeks 17 to 21 Visits
Tidsramme: Baseline, Weeks 17 to 21
|
Baseline, Weeks 17 to 21
|
Part 1 (ESA-Naïve): Percentage of Participants With Mean Hb (Averaged Weeks 17 to 21 Visits) ≥100 g/L
Tidsramme: Weeks 17 to 21
|
Weeks 17 to 21
|
Part 2: Percentage of Participants With Mean Hb (Averaged Weeks 33 to 37 Visits) ≥100 g/L
Tidsramme: Weeks 33 to 37
|
Weeks 33 to 37
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FGCL-4592-818
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på CKD Anemia in Dialysis Participants
-
King's College Hospital NHS TrustKing's College London; University of LeicesterFullført
-
FibroGenAstraZeneca; Astellas Pharma Europe B.V.FullførtCKD anemi hos stabile dialysepasienterForente stater, Puerto Rico
-
Assiut UniversityRekrutteringGut Micrbota og dens forhold til anemi hos CKD-pasienterEgypt
-
FibroGenAstraZeneca; Astellas Pharma Europe B.V.FullførtCKD anemiForente stater, Australia, Thailand, Korea, Republikken, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Filippinene, Puerto Rico, Singapore
-
AMAG Pharmaceuticals, Inc.FullførtBehandling av jernmangelanemi | Kronisk nyresykdom (CKD)Forente stater, Canada, Storbritannia
-
AmgenFullførtAnemi | Kronisk nyresykdom (CKD)Østerrike, Ungarn, Spania, Bulgaria, Polen, Hellas, Tsjekkisk Republikk, Italia
-
VA Office of Research and DevelopmentAvsluttetAterosklerose | Anemi | CKD | KardiovaskulærForente stater
-
SandozFullførtAnemi | Kronisk nyresykdom (CKD)Forente stater
-
Gliknik Inc.RekrutteringFirst in Man-studie for å evaluere innledende sikkerhetStorbritannia
-
University of Alabama at BirminghamAmerican Heart AssociationTilbaketrukketKroniske nyresykdommer | Jernmangel | Anemi | CKD | Vitamin d | Hepcidin | ErgocalciferolForente stater
Kliniske studier på Roxadustat
-
Astellas Pharma IncFibroGenFullført
-
Astellas Pharma IncFibroGenFullførtESA-naive hemodialyse pasienter med kronisk nyresykdom med anemiJapan
-
Astellas Pharma IncFibroGenFullførtPeritoneal Dialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Mao JianhuaRekrutteringAnemi assosiert med kronisk nyresykdomKina
-
Sunshine Lake Pharma Co., Ltd.Nicoya Therapeutics (Shanghai) Co., Ltd.Har ikke rekruttert ennåKroniske nyresykdommer | NyreanemiKina
-
FibroGenAstraZenecaTilbaketrukketAnemi assosiert med kronisk nyresykdomForente stater
-
FibroGenAstraZeneca; Astellas Pharma IncFullførtKjemoterapiindusert anemiForente stater
-
Astellas Pharma Europe B.V.FibroGenFullførtNedsatt nyrefunksjon | Normal nyrefunksjonTyskland, Storbritannia
-
Astellas Pharma Global Development, Inc.FibroGenFullført
-
Astellas Pharma IncFullførtAnemi | Hemodialyse | Nedsatt nyrefunksjonJapan